Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

NSE:THEMISMED

THEMIS MEDICARE LTD.

Healthcare › Pharmaceuticals & Biotechnology

₹100.55

at close · 6 Nov 2026

▼ 1.37 (-1.34%)

Next results in 8d Get alerts

Latest filings

Next results: Sat, 14 Nov · Financial Results

Mon, 2 NovThemis Medicare reschedules November board meeting · Compliance
Fri, 30 OctEncumbered Themis holding rises to 35.09% after 4 million additional shares pledged · Ownership Changes
Wed, 28 OctPromoter pledges 2.5 million shares for debentures · Ownership Changes

All filings ↓

Ask Nexa about THEMIS MEDICARE LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹332 Cr over the trailing twelve months.

Market Cap

₹924 Cr

P / E (TTM)

23.1×

EV / EBITDA

—

Div Yield

0.50%

Growth

8.2%▲

Revenue 5y CAGR

PAT -49.8% · EBITDA -62.0%

Quality

10.7%·

ROCE (5y median)

ROE 11.5% (5y median) · margin 0.1%

Leverage

0.25·

Debt / Equity · low

Net debt ₹96 Cr

Revenue FY21→FY26

1.5×▲

Margin −15.1 pts

₹231 Cr → ₹342 Cr

Cash conversion

0.47×▼

Operating cash ÷ profit · 5 yrs

₹96 Cr on ₹204 Cr

Moves on a normal day

1.66%·

Median daily move

Last 268 sessions · the yardstick for filing-day moves

Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures

P/E (TTM)#63/160

P/B#66/163

ROCE#155/177

ROE#142/165

Debt / Equity#107/166

EBITDA margin#175/179

Revenue growth#130/162

Profit growth#20/157

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths

Nothing stands out in the filed numbers.

Concerns

Profit shrinking over 5 years (−50% a year)

Erratic profits — up in only 1 of the last 5 years

Over 5 years it reported ₹204 Cr of profit and ₹96 Cr of operating cash — 0.47×

Less than 60p of every ₹1 of profit arrived as cash

Heavy working capital — 222 days of cash tied up

Customers are taking longer to pay — 123 → 190 days of receivables

FY21 → FY26

EPS grew slower than profit — the share count rose (bonus or dilution)

Charts

How has the market priced it — with filings on the timeline?

THEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Governance

Is the board independent, clean and well-run?

Sustainability

What's the ESG footprint — and which way is it moving?

Compliance

Did a company secretary sign off that it's clean?

Audit Report

What the auditor actually said — opinion, key audit matters, CARO clauses.

Earnings Call

What management said — and how it landed.

Investor Presentation

An AI read of the latest deck — verdict, KPIs, key slides and what it promised.

Events

Board meetings and results dates, upcoming and recent.

Reactions

How does the stock move after this company files?

Filings

The full disclosure feed.

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from THEMIS MEDICARE LTD.'s filed financials and exchange disclosures

What does THEMIS MEDICARE LTD. do?

THEMIS MEDICARE LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol THEMISMED.

Is THEMIS MEDICARE LTD. profitable?

Yes. Over the trailing twelve months THEMIS MEDICARE LTD. reported a net profit of ₹40 Cr on revenue of ₹332 Cr.

Does THEMIS MEDICARE LTD. pay a dividend?

Yes. The dividend yield is 0.50% at the current price. It paid out 402% of its profit as dividend in FY26.

Is THEMIS MEDICARE LTD. debt-free?

No. It reported borrowings of ₹100 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹96 Cr after cash. Debt stands at 0.25× equity. That is higher than 64% of its 166 Pharmaceuticals peers.

Is THEMIS MEDICARE LTD. expensive compared with its peers?

On trailing P/E, THEMIS MEDICARE LTD. ranks 63 of 160 in Pharmaceuticals — cheaper than 61% of them, against an industry median of 28.7×. This is a position, not a valuation judgement.

How much does the THEMIS MEDICARE LTD. share price move in a day?

On a typical session THEMIS MEDICARE LTD. moves 1.66% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

When are THEMIS MEDICARE LTD.'s next results?

Financial Results on Sat, 14 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track THEMIS MEDICARE LTD.'s announcements?

Every NSE and BSE filing by THEMIS MEDICARE LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.